Aurobindo PharmaBOM:524804 +1.65%85 EBITDA Margin % is 21.34% as of Mar. 2026, which is 1% below its 10-year median of 21.59. GuruFocus rates BOM:524804 with a GF Score™ of 85/100 and a GF Value™ of ₹1,322.24 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 952 Drug Manufacturers companies, Aurobindo Pharma ranks better than 72.48% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aurobindo Pharma's EBITDA for the
three
months ended in Mar. 2026 was ₹18,674 Mil. Aurobindo Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹87,515 Mil. Therefore, Aurobindo Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 21.34%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aurobindo Pharma EBITDA Margin % Related Terms
Aurobindo Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Aurobindo Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524804 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurobindo Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aurobindo Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurobindo Pharma (BOM:524804) has a EBITDA Margin % of 21.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aurobindo Pharma and its competitors. This is near median its historical median of 21.59. Over the past decade, Aurobindo Pharma's EBITDA Margin % has ranged from 16.19 to 34.44. According to the industry distribution chart, Aurobindo Pharma ranks #262 out of 952 companies in the Drug Manufacturers industry, placing it in the top 27.5%.
Is Aurobindo Pharma's EBITDA Margin % too high?
Aurobindo Pharma's current EBITDA Margin % of 21.34% is near median its 10-year median of 21.59. Over the past 10 years, this metric has ranged from a low of 16.19 to a high of 34.44. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Aurobindo Pharma's value of 21.34% is 71.1% above this industry median. Based on the distribution chart, Aurobindo Pharma ranks #262 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aurobindo Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurobindo Pharma's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aurobindo Pharma ranks #262 out of 952 companies for EBITDA Margin %. This puts Aurobindo Pharma in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Aurobindo Pharma's value of 21.34% is 71.1% above this benchmark. Historically, Aurobindo Pharma's own EBITDA Margin % has ranged from 16.19 to 34.44 over the past decade. While the company's 10-year median is 21.59 vs. the industry median of 12.47, Aurobindo Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurobindo Pharma's current EBITDA Margin % of 21.34% is 71.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aurobindo Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurobindo Pharma's current EBITDA Margin % is 21.34%, which is near median its own 10-year median of 21.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurobindo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,322.24, compared to a current price of ₹1,554.95 — trading 17.6% above its estimated fair value. The current EBITDA Margin % is 21.34%, which is near median its 10-year median of 21.59 and 71.1% above the Drug Manufacturers industry median of 12.47. Aurobindo Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current EBITDA Margin % is 21.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?
Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued.
The current stock price of ₹1,554.95 is trading 17.6% above its estimated GF Value™ of ₹1,322.24.
GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524804:
EBITDA Margin %: 21.34% (near median its 10-year median of 21.59)
GF Value™: ₹1,322.24 vs. price of ₹1,554.95 (17.6% above fair value)
Industry Position: 71.1% above the Drug Manufacturers median (#262 of 952)
No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
85GF Score
Get the complete analysis for BOM:524804
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524804 has been successfully added to your 
